help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoshimoto, T.
Right arrow Articles by Demura, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoshimoto, T.
Right arrow Articles by Demura, H.

Endocrinology, Vol 137, 1102-1107, Copyright © 1996 by Endocrine Society


ARTICLES

Angiotensin II-dependent down-regulation of vascular natriuretic peptide type C receptor gene expression in hypertensive rats

T Yoshimoto, M Naruse, K Naruse, K Shionoya, M Tanaka, A Tanabe, H Hagiwara, S Hirose, T Muraki and H Demura
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical College, Japan.

Biological actions of natriuretic peptide (NP) are determined by the condition of the receptor as well as that of the hormone. Although we previously demonstrated in hypertensive rats the up-regulation of NP-A receptor that mediates various biological actions of NPs, the pathophysiologic significance of NP-C receptor, another subtype thought to be related to clearance of NPs and possibly to biological actions, remains unknown. In the present study, we determined NP-C receptor messenger RNA (mRNA) level in the aortic tissue of stroke-prone spontaneously hypertensive rats (SHR-SP/Izm) and in cultured aortic smooth muscle cells by ribonuclease protection assay. The aortic NP-C receptor mRNA level in SHR-SP/Izm was significantly lower than that in the control WKY/Izm. Oral administration of an angiotensin (Ang) II receptor (AT1) antagonist, TCV-116, but not a calcium channel blocker, manidipine, reversed the down-regulated NP-C receptor mRNA in SHR- SP/Izm to the level in WKY/Izm, whereas the latter was more potent in decreasing the blood pressure. In cultured aortic smooth muscle cells, the NP-C receptor was the predominant subtype. Ang II decreased the NP- C receptor mRNA level in a dose-dependent manner, but this effect was reversed by an AT1 antagonist, CV-11974. Neither the NP-A nor NP-B receptor mRNA level was altered by Ang II. These findings indicate that vascular NP-C receptor is down- regulated via Ang-II-mediated mechanism in SHR-SP/Izm. The phenomenon, together with the up-regulation of the NP-A receptor, may play an important role in counteracting hypertension by enhancing the action of NPs.


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
Y. Shimokawa, K.-i. Hirata, T. Ishida, Y. Kojima, N. Inoue, T. Quertermous, and M. Yokoyama
Increased expression of endothelial lipase in rat models of hypertension
Cardiovasc Res, June 1, 2005; 66(3): 594 - 600.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Yoshimoto, N. Fukai, R. Sato, T. Sugiyama, N. Ozawa, M. Shichiri, and Y. Hirata
Antioxidant Effect of Adrenomedullin on Angiotensin II-Induced Reactive Oxygen Species Generation in Vascular Smooth Muscle Cells
Endocrinology, July 1, 2004; 145(7): 3331 - 3337.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
N. Yanaka, J. Kotera, and K. Omori
Isolation and Characterization of the 5'-Flanking Regulatory Region of the Human Natriuretic Peptide Receptor C Gene
Endocrinology, March 1, 1998; 139(3): 1389 - 1400.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Yoshimoto, M. Naruse, A. Tanabe, K. Naruse, T. Seki, T. Imaki, T. Muraki, Y. Matsuda, and H. Demura
Potentiation of Natriuretic Peptide Action by the {beta}-Adrenergic Blocker Carvedilol in Hypertensive Rats: A New Antihypertensive Mechanism
Endocrinology, January 1, 1998; 139(1): 81 - 88.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society